central-nervous-system-2016_posters-accepted-abstracts

3 / 42

Notes:
Page 59
CNS 2016
December 05-07, 2016
Volume 7, Issue 5(Suppl) J Neurol Neurophysiol
ISSN: 2155-9562 JNN, an open access journal
conferenceseries .com
December 05-07, 2016 Dubai, UAE
2nd International Conference on
Central Nervous System Disorders & Therapeutics
Elena Solntseva et al., J Neurol Neurophysiol 2016, 7:5(Suppl)
Glycine receptor in hippocampal neurons as a target for lithium ions
Elena Solntseva and Julia Bukanova
Research Center of Neurology, Russia
Lithium salts are successfully used to treat bipolar disorder. At the same time, according to recent data lithium may be
considered as a candidate medication for the treatment of neurodegenerative disorders. The mechanisms of therapeutic
action of lithium have not been fully elucidated. In particular, in the literature there are no data on the effect of lithium on the
glycine receptors. In the present study we investigated the effect of Li+ on glycine-activated chloride current (IGly) in rat isolated
pyramidal hippocampal neurons using patch-clamp technique. Short (600 ms) application of Li+ caused two effects: (1) an
acceleration of desensitization (a decrease in the time of half-decay, or “τ”) of IGly and (2) a reduction of the peak amplitude of
the IGly, Both effects were not voltage-dependent. Dose-response curves for both effects were N-shaped with two maximums
at 100nM and 1mM of Li+ and a minimum at 1 µM of Li+. This complex form of dose-response may indicate that the process
activated by high concentrations of lithium inhibits the process that is sensitive to low concentrations of lithium. Longer
application (10 min) of Li+ caused similar effects, but in this case 1µM lithium was effective and the dose-effect curves were
not N-shaped. The inhibitory effect of lithium ions on glycine-activated current suggests that lithium in low concentrations is
able to modulate tonic inhibition in the hippocampus. This important property of lithium should be considered when using
this drug as a therapeutic agent.
Biography
Elena Solntseva graduated from the Lomonosov Moscow State University (Moscow, Russia) with a degree "neuroscience". She then worked at the Center for
Mental Health in Moscow, where she defended her PhD thesis and then a Doctoral thesis. She currently works at the Research Center of Neurology in Moscow.
She is the author of dozens of scientific publications.